1-3 of 3
Chris J. O'Callaghan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial

Jonathan M. Loree, Emma Titmuss, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, Shakeel Virk, Young S. Lee, Kimberly Banks, Katie Quinn, Aly Karsan, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3189–3199.
https://doi.org/10.1158/1078-0432.CCR-24-0268
Published: 01 August 2024
View article titled, Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Open the PDF for Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial in another window
Includes: Supplementary data
Journal Articles

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials

Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, Dongsheng Tu, Stephanie Y. Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian Siu, Jeremy Shapiro, John Simes, Sharlene Gill, Chris J. O'Callaghan, Jonathan M. Loree
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1121–1130.
https://doi.org/10.1158/1078-0432.CCR-23-3275
Published: 15 March 2024
View article titled, Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Open the PDF for Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

Jonathan M. Loree, Anthony Dowers, Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O'Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, Scott Kopetz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 52–59.
https://doi.org/10.1158/1078-0432.CCR-20-2710
Published: 04 January 2021
View article titled, Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Open the PDF for Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial in another window
Includes: Supplementary data